XCHO.OB: Summary for XENACARE HOLDINGS - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 8:17am EST - Canadian Markets open in 1 hour and 13 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Xenacare Holdings Inc. (XCHO.OB)

On Nov 24: 0.079 USD 0.00 (0.00%)

MORE ON XCHO.OB

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

XENACARE HOLDINGS (OTC BB:XCHO.OB) Delayed quote data

Last Trade:	0.079 USD
Trade Time:	Nov 24
Change:	0.00 (0.00%)
Prev Close:	0.079
Open:	N/A
Bid:	0.078 x 5000
Ask:	0.085 x 5000
1y Target Est:	N/A

Day's Range:	N/A - N/A
52wk Range:	0.01 - 0.32
Volume:	0
Avg Vol (3m):	449,602
Market Cap:	4.21M
P/E (ttm):	N/A
EPS (ttm):	-0.037
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y

Add XCHO.OB to Portfolio

Download Data

HEADLINES

•	XENACARE HOLDINGS, INC. Financials
	EDGAR Online Financials (Sat, Nov 21)

•	XENACARE HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Mon, Nov 16)

•	XenaCare Holdings Announces Availability of Cobroxin through the Chain Drug Marketing Association (CDMA)
	Business Wire (Wed, Nov 4)

•	XenaCare Holdings Announces Agreement to Market its Over-the-Counter Pain Reliever, Cobroxin, in the Official Annual Publication of NASCAR
	Business Wire (Thu, Oct 22)

•	XenaCare Holdings Announces Agreement to Market OTC Pain Reliever, Cobroxin, in the National Football League (NFL) Alumni Association Publication
	Business Wire (Tue, Oct 20)

•	Nutra Pharma Announces Online Availability of Cobroxin for the Treatment of Moderate to Severe Chronic Pain
	Business Wire (Wed, Oct 14)

•	XENACARE HOLDINGS, INC. Files SEC form 10-Q/A, Quarterly Report
	EDGAR Online (Fri, Oct 2)

•	Nutra Pharma Announces Manufacturing Release of Cobroxin, a Treatment for Chronic Pain
	Business Wire (Fri, Oct 2)

•	Nutra Pharma Announces Plans to Begin Drug Registration Process in Canada and Europe for its Over-the-Counter Pain Reliever
	Business Wire (Mon, Sep 21)

•	XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
	Business Wire (Thu, Sep 3)

More Headlines for XCHO.OB...

BUSINESS SUMMARY

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution of nutrition supplement products primarily in the United States. Its clinical products include XenaCor, which lowers serum cholesterol, C-reactive protein, and homocys...

Full Company Profile

Add to Portfolio

Email to a Friend

•